Recent Projects - Pricing and Reimbursement

Recent pricing and reimbursement projects carried out by the Bridgehead team include the following:

Benign prostate hyperplasia

Bridgehead's client had previously launched a new product indicated for treatment of locally advanced and advanced prostate cancer. This product was now entering Phase II trials for the treatment of benign prostate hyperplasia (BPH). The company commissioned the Market Access Strategy team of Bridgehead International to help it understand the potential to achieve an attractive price in the US for the BPH indication. For futher information. For futher information

An American life science company had in-licensed the commercial rights to a new biomarker for coronary heart failure. The company was in the process of preparing for market entry into Europe and sought to understand the reimbursement fundamentals in each of the target markets under consideration. They looked to Bridgehead to provide them with a review of the reimbursement landscape for its technology in Europe (UK, Germany, France, Italy, and Spain) and the Nordic Countries (Sweden, Denmark, Finland, Norway). For further information

Bridgehead's client was preparing to launch a product that would potentially be an important predictive diagnostic test of ventricular dysfunction, heart failure and other heart complications. The client wanted a value proposition for the product to be developed; Bridgehead prepared a payer dossier and conducted a payer/clinician advisory panel. For futher information

Bridgehead was retainedto refine this client's reimbursement plan with specific focus on questions related to likely coverage scenarios by payers, differential reimbursement rates for existing codes, and implications of different pricing related to the packaging of the client’s product. For further information

A global pharmaceutical company had a number of peri-and post-LOE assets that were to face significant generic pressures. As the generics would increasingly compete on price and drive down margins over time, the client wanted Bridgehead to help them understand what strategies could support increased pricing after LOE and assess the potential for price modulation of key mature brands in the US market. For further information

An international pharmaceutical company commissioned the Market Access Strategy team of Bridgehead International to support the development of a strategic launch package for a MS-related symptom relief product in late stage development for Spain. They requested that Bridgehead design and implement a primary and secondary research programme which would then inform the development of a Pricing and Reimbursement dossier, budget impact and cost effectiveness models that would be presented to the Ministry of Health in Spain. For further information